Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27625049 | 0.90 | NAAA (0.45) | ALDH1A1HTTCNR1CNR2NAAA | |
| SCHEMBL28337063 | 0.84 | ALDH1A1 (0.39) | ALDH1A1CNR1CNR2SMN1; SMN2NPC1 | |
| SCHEMBL28141407 | 0.80 | PPARA (0.42) | ALDH1A1HTTNAAA | |
| SCHEMBL18489615 | 0.79 | PPARA (0.41) | CNR2 | |
| SCHEMBL28649757 | 0.79 | PPARA (0.44) | ALDH1A1HTTCNR1CNR2MAPT | |
| SCHEMBL27951175 | 0.79 | PPARA (0.44) | ALDH1A1HTTCNR1CNR2MAPT | |
| SCHEMBL7939821 | 0.77 | SCN1A (0.54) | ALDH1A1HTTCNR1CNR2NAAA | |
| SCHEMBL11118770 | 0.77 | PPARA (0.49) | ALDH1A1HTTCNR1CNR2NAAA | |
| SCHEMBL7190804 | 0.76 | TYR (0.39) | HTTCNR1CNR2MAPTMEN1 | |
| SCHEMBL27907225 | 0.74 | PPARA (0.48) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897559-A1 | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | Cydex Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897560-A1 | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | Cydex Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1876914-A2 | LIGNAN-CONTAINING COMPOSITIONS | Archer-Daniels-Midland Company (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1859790-A2 | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | Cydex Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1140960-B1 | SULFOALKYL ETHER CYCLODEXTRIN BASED CONTROLLED RELEASE SOLID PHARMACEUTICAL FORMULATIONS | CYDEX INC (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1799759-A1 | 4-PHENYLBUTYRIC ACID CONTROLLED-RELEASE FORMULATIONS FOR THERAPEUTIC USE | Lunamed Inc. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20060234948-A1 | Lignan-containing compositions | ARCHER -DANIELS- MIDLAND COMPANY | 2006-10-19 | — | — | US | disclosed |
| WO-2006107820-A2 | LIGNAN-CONTAINING COMPOSITIONS | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006059237-A1 | 4-PHENYLBUTYRIC ACID CONTROLLED-RELEASE FORMULATIONS FOR THERAPEUTIC USE | LUNAMED, INC. (CH) | 2006-06-08 | — | — | WO | disclosed |
| US-20060045912-A1 | 4-phenylbutyric acid controlled-release formulations for therapeutic use | LUNAMED, INC. (CH) | 2006-03-02 | — | — | US | disclosed |
| EP-1140960-A4 | SULFOALKYL ETHER CYCLODEXTRIN BASED CONTROLLED RELEASE SOLID PHARMACEUTICAL FORMULATIONS | CYDEX INC (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0980262-B1 | SOLID PHARMACEUTICAL FORMULATIONS CONTAINING A PHYSICAL MIXTURE OF SULFOALKYL ETHER CYCLODEXTRIN AND A THERAPEUTIC AGENT | CYDEX INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6521247-B1 | Dual iron containing nutritional supplement | WARNER CHILCOTT LABORATORIES IRELAND LIMITED | 2003-02-18 | — | — | US | disclosed |
| EP-1140960-A1 | SULFOALKYL ETHER CYCLODEXTRIN BASED CONTROLLED RELEASE SOLID PHARMACEUTICAL FORMULATIONS | Cydex Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001012163-A1 | DUAL IRON-CONTAINING NUTRITIONAL SUPPLEMENT | WARNER CHILCOTT LABORATORIES IRELAND LIMITED (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000041704-A1 | SULFOALKYL ETHER CYCLODEXTRIN BASED CONTROLLED RELEASE SOLID PHARMACEUTICAL FORMULATIONS | CYDEX, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| US-6046177-A | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | CYDEX, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0980262-A1 | SOLID PHARMACEUTICAL FORMULATIONS CONTAINING A PHYSICAL MIXTURE OF SULFOALKYL ETHER CYCLODEXTRIN AND A THERAPEUTIC AGENT | Cydex Inc. (US) | 2000-02-23 | — | — | EP | disclosed |
| US-5874418-A | SUSTAINED RELEASE | CYDEX, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998050077-A1 | SOLID PHARMACEUTICAL FORMULATIONS CONTAINING A PHYSICAL MIXTURE OF SULFOALKYL ETHER CYCLODEXTRIN AND A THERAPEUTIC AGENT | CYDEX INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060045912-A1 | 4-phenylbutyric acid controlled-release formulations for therapeutic use | SLC6A13, SLC6A11, SLC6A1 | ALDH1A1 1980/4885HTT 176/4885CNR1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.